A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oc ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Indigenous communities in Latin America say they are missing out on life-saving HIV drugs due to a lack of representation.

The increasing incidence of sexually transmitted bacterial infections (STIs) is a major public health problem worldwide.

Cases of HIV amongst heterosexual patients in England has risen by more than 30% since 2022. Data from the UKHSA found that ...

1 The phase 3 PURPOSE 2 trial is assessing lenacapavir as a pre-exposure prophylaxis (PrEP) medicine to reduce the chance of getting HIV through sex, comparing it when taken twice per year as PrEP ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP) use in priority populations with unmet needs for PrEP in the U.S. Additional HIV research findings ...

Chaphalkar, PhD.New research reveals that doxycycline post-exposure prophylaxis raises resistance gene levels in the gut, but ...

After launching its “Plan First!” program just over a year ago, the Michigan Department of Health and Human Services says the ...